Effect of dutasteride on the risk of prostate cancer.

By G. Andriole, D. Bostwick, O. Brawley, L. Gomella, M. Marberger, F. Montorsi, C. Pettaway, T. Tammela, C. Teloken, D. Tindall and 4 more. New England Journal of Medicine, 2010

1,111 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Urology

View Paper: https://www.semanticscholar.org/paper/86cd47fa2c770a7040df91c557925a0997f9f468

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Bachmann
2. J. de la Rosette
3. M. Oelke
4. A. Descazeaud
5. A. Salonia
6. A. Gallina
7. J. N'Dow
8. R. Colombo

Citations in the corpus

• EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. (2013, methodology): “Data from two important trials on Prostate Cancer chemoprevention (the Prostate Cancer Prevention Trial and the Reduction by Dutasteride of Prostate Cancer Events trial) found a higher incidence of high-grade cancers in the 5-ARI arms compared with placebo arms [38,39].”
• Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy (2012, background): “Translationally, the 2 largest trials that investigated the use of 5ARIs showed an overall relative reduction of 23% to 25% in prostate cancer diagnoses, with an absolute increase in the incidence of high-grade prostate cancer in the chemoprevention group in both trials (48, 49).”